Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adverse reactions to biological modifiers.

Richard W Weber1

  • 1Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA. weberr@njc.org

Current Opinion in Allergy and Clinical Immunology
|July 9, 2004
PubMed
Summary

Biologic immunomodulators like interferons and TNFalpha inhibitors help manage inflammatory conditions but can cause adverse events. Careful patient selection is key to minimizing risks associated with these advanced therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tree pollen allergen sensitization: Prevalence, risk factors, and geographic variation in the United States.

The journal of allergy and clinical immunology. Global·2026
Same author

Current and Future Effects of Climate Change on Airborne Allergens.

Current allergy and asthma reports·2024
Same author

Assessing cross-reactivity in allergen immunotherapy.

Allergy and asthma proceedings·2022
Same author

Allergy to oak pollen in North America.

Allergy and asthma proceedings·2021
Same author

Allergen of the Month-Japanese Maple.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2015
Same author

Allergen of the Month--English Oak.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2015

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Biologic immunomodulators, including interferons, tumor necrosis factor alpha (TNFalpha) inhibitors, and monoclonal antibodies, are increasingly used for inflammatory conditions.
  • These novel agents offer therapeutic advancements but are associated with potential adverse responses.

Purpose of the Study:

  • To review the adverse responses associated with newer biologic immunomodulators.
  • To highlight the risks and concerns related to these advanced therapies in managing inflammatory diseases.

Main Methods:

  • Literature review of adverse events associated with biologic immunomodulators.
  • Analysis of reported side effects and immunological reactions to interferons, TNFalpha inhibitors, and monoclonal antibodies.

Related Experiment Videos

Main Results:

  • Interferon-alpha and interferon-beta are linked to autoimmune phenomena.
  • TNFalpha antagonists can cause significant adverse reactions, either by interfering with TNFalpha activity or due to immune responses against the agents themselves (immunoglobulin or fusion protein).

Conclusions:

  • Biologic modifiers represent significant advancements in treating inflammatory conditions.
  • However, these agents carry substantial risks, necessitating careful patient selection and identification of at-risk groups to minimize adverse events.